PALO ALTO, Calif. & DELRAY BEACH, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--$GIX--GigCapital2, Inc. (“GigCapital2”) (NYSE: GIX, GIX.U, GIX.RT, and GIX.WS) announced...
PORTLAND, Ore.--(BUSINESS WIRE)--#BioPro--With large company expansions such as Micro Systems Engineering’s upcoming Lake Oswego-area advanced automated manufacturing expansion, Genentech’s Hillsboro...
Toronto, Ontario--(Newsfile Corp. - June 4, 2021) - Leveljump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the...
FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech...
HAMPTON, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preliminary data from the Company’s Phase...
SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development...
RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results...
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19) Triple combination of ublituximab and UKONIQ...
Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to...
- INNATE trial to include proof-of-concept expansion cohorts in lung, renal, head and neck, triple negative breast, cutaneous squamous cell,...
CLN-081 Continues to Demonstrate Acceptable Overall Safety and Tolerability, With Encouraging GI Toxicity ProfileAs of the Data Cutoff, No Grade...
Poster showcases positive preliminary data from first 20 patients treated with the HER2-targeting Boltbody™ ISAC BDC-1001 as of January 29th...
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific...
Glycotope Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, June 4, 2021...
UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData...
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patientsDURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE)...
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination...
100% (12/12) of patients with relapsed and refractory multiple myeloma treated with Arcellx’s BCMA-specific CAR-modified T-cell therapy achieved responses per...
Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant...